 SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 GLOBE NEWSWIRE -- Atreca, Inc. Atreca NASDAQ: BCEL, a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences: 2020 Wedbush PacGrow Healthcare Virtual Conference Wednesday, August 12, 2020 Presentation time: 2:20 p.m. EDTCanaccord Genuity 40th Annual Growth Conference Thursday, August 13, 2020 Presentation time: 4:00 p.m. EDTLive webcasts of each event can be accessed through the Events Presentations section of the Companys website at ir.atreca.com. Archived replays of the webcasts will be available on the Companys website for 90 days following the live presentations.About Atreca, Inc. Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atrecas platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit Atreca, Inc. Herb Cross Chief Financial Officer Alex Gray, 650-779-9251, ext. 251 Sheryl Seapy, 213-262-9390 Atreca, Inc. 